Home

Content about National Cancer Institute

03.12.10
Genentech announces topline results from Phase III trial of Avastin

Genentech, Inc., a wholly owned member of the Roche Group, announced today the topline results of a Phase III trial led by the U.S. Cancer and Leukemia Group B (CALGB) and sponsored by the National Cancer Institute investigating the use of Avastin® (bevacizumab) in combination with docetaxel chemotherapy and prednisone in men with late stage prostate cancer (hormone-refractory / HRPC).

02.06.10
HPV vaccination programs may reduce genital diseases

High-coverage human papillomavirus (HPV) vaccinations among adolescents and young women may result in a rapid reduction of genital warts, cervical cell abnormalities, and diagnostic and therapeutic procedures, researchers report in a new study published online February 5 in the Journal of the National Cancer Institute. Some of these genital abnormalities are precursors of cervical, vulvar, and vaginal cancers.

01.08.10
Variants in CRP gene not associated with increased risk of cancer

Gene variants associated with increased circulating levels of C-reactive protein, a marker of inflammation, are not associated with an increased risk of cancer, according to a new brief communication published online January 7 in the Journal of the National Cancer Institute.

12.22.09
MSH6 mutation carriers at elevated risk for colorectal, endometrial and lynch syndrome cancers

People carrying the germ-line MSH6 mutation are at high risk by age 80 years for colorectal and endometrial cancers and any cancer associated with Lynch syndrome, according to a new study published online December 22 in the Journal of the National Cancer Institute.

11.17.09
Bladder Cancer Risks Increase Over Time For Smokers

Risk of bladder cancer for smokers has increased since the mid-1990s, with a risk progressively increasing to a level five times higher among current smokers in New Hampshire than that among nonsmokers in 2001-2004, according to a new study published online November 16 in the Journal of the National Cancer Institute.

11.11.09
Erythropoiesis-Stimulating Agents Associated With Higher Risk Of Venous Thromboembolism

Use of erythropoiesis-stimulating agents is associated with an increased risk of venous thromboembolism, according to study published online November 10 in the Journal of the National Cancer Institute. Erythropoiesis-stimulating agents (i.e.

06.19.09
Hodgkin Lymphoma Survivors Have Increased Risk Of Stroke And Transient Ischemic Attack

Patients treated for Hodgkin lymphoma with radiation therapy have a substantially higher risk of stroke, according to a new study published June 17 online in the Journal of the National Cancer Institute. The study was undertaken because information on clinically verified stroke and transient ischemic attack (TIA), or a "mini stroke," following Hodgkin lymphoma is limited. In order to quantify the long-term risks, Flora E. van Leeuwen, Ph.D.

04.30.09
Dietary acrylamide not linked to increased lung cancer risk in men

Dietary acrylamide was not associated with an increased risk of lung cancer, according to data from a large prospective case-cohort study in the April 28 online issue of the Journal of the National Cancer Institute.

04.11.09
More Intensive Treatment Not Associated With Better Outcomes In Early Bladder Cancer

Patients with early bladder cancer who receive more intensive treatment within the first two years of diagnosis do not appear to have better survival than patients who receive less intensive treatment, according to a retrospective analysis published in the April 7 online issue of the Journal of the National Cancer Institute.